XPro1595, an investigational therapy by INmune Bio, can lower brain inflammation in people with mild to moderate Alzheimer’s disease, according to interim results of a clinical trial. Specifically, the Phase 1b clinical trial (NCT03943264) shows evidence that XPro1595 decreases white matter free water, a biomarker of neuroinflammation measured by magnetic resonance imaging (MRI). XPro1595 was designed to lower inflammation by selectively neutralizing soluble tumor necrosis factor (sTNF), an inflammatory cell signaling molecule, or cytokine, implicated…
You must be logged in to read/download the full post.
The post XPro1595 Lowers Neuroinflammation in Mild to Moderate Alzheimer’s, Interim Results Show appeared first on BioNewsFeeds.